Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
BRIDGEWATER, N.J., April 27, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will release its first quarter 2017 financial results on Friday, May 12, 2017 before the market opens.
Valeritas will hold a conference call on Friday, May 12, 2017 at 8:30 a.m. EDT / 5:30 a.m. PDT to discuss the results. The dial-in numbers are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers. The conference ID number is 6235006. A live webcast of the conference call will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com.
If you are unable to participate during the live webcast, a replay will remain available until Valeritas reports its second quarter 2017 financial results on the investor relations page of the Valeritas corporate website at www.valeritas.com. In addition, a telephonic replay of the call will be available through May 13, 2017. The replay dial-in numbers are (800) 585-8367 for domestic callers and (416) 621-4642 for international callers. Please use the replay pin number 6235006.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group (646)536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group (508)280-6592 [email protected]
